| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Heart Failure | 4 | 2023 | 38 | 2.050 |
Why?
|
| Mitral Valve Insufficiency | 4 | 2019 | 11 | 1.920 |
Why?
|
| Cardiomyopathy, Dilated | 2 | 2023 | 35 | 1.670 |
Why?
|
| Heart Diseases | 3 | 2018 | 19 | 1.630 |
Why?
|
| Acute Coronary Syndrome | 4 | 2020 | 13 | 1.610 |
Why?
|
| HIV | 4 | 2021 | 380 | 1.550 |
Why?
|
| Coronary Artery Disease | 4 | 2021 | 30 | 1.500 |
Why?
|
| HIV Infections | 12 | 2021 | 5097 | 1.460 |
Why?
|
| Adrenergic beta-Antagonists | 3 | 2019 | 9 | 1.270 |
Why?
|
| Percutaneous Coronary Intervention | 4 | 2021 | 12 | 1.240 |
Why?
|
| Ventricular Remodeling | 2 | 2019 | 44 | 1.210 |
Why?
|
| Humans | 48 | 2023 | 14537 | 1.170 |
Why?
|
| Coronary Stenosis | 2 | 2019 | 4 | 1.140 |
Why?
|
| Cardiovascular Diseases | 5 | 2022 | 237 | 1.110 |
Why?
|
| Takotsubo Cardiomyopathy | 2 | 2016 | 2 | 1.090 |
Why?
|
| Ventricular Function, Left | 4 | 2023 | 80 | 1.070 |
Why?
|
| Risk Factors | 15 | 2020 | 1475 | 1.030 |
Why?
|
| Middle Aged | 19 | 2023 | 3601 | 0.940 |
Why?
|
| Male | 30 | 2023 | 6754 | 0.920 |
Why?
|
| Bioprosthesis | 5 | 2003 | 8 | 0.890 |
Why?
|
| Endothelium, Vascular | 2 | 2022 | 29 | 0.880 |
Why?
|
| Myocardial Infarction | 4 | 2021 | 24 | 0.870 |
Why?
|
| Thrombosis | 2 | 2021 | 47 | 0.860 |
Why?
|
| Adult | 23 | 2023 | 5913 | 0.800 |
Why?
|
| Renal Insufficiency, Chronic | 6 | 2020 | 69 | 0.770 |
Why?
|
| Ventricular Dysfunction, Left | 2 | 2019 | 47 | 0.770 |
Why?
|
| Heart Rate | 2 | 2019 | 32 | 0.760 |
Why?
|
| Female | 29 | 2023 | 9103 | 0.760 |
Why?
|
| Atherosclerosis | 6 | 2020 | 100 | 0.740 |
Why?
|
| Heart Valve Prosthesis | 4 | 2003 | 9 | 0.710 |
Why?
|
| Vasodilation | 1 | 2020 | 7 | 0.700 |
Why?
|
| Ultrasonography, Interventional | 2 | 2019 | 10 | 0.700 |
Why?
|
| Plaque, Atherosclerotic | 2 | 2019 | 27 | 0.690 |
Why?
|
| Vascular Stiffness | 1 | 2020 | 41 | 0.660 |
Why?
|
| ST Elevation Myocardial Infarction | 1 | 2019 | 4 | 0.660 |
Why?
|
| Treatment Outcome | 10 | 2021 | 889 | 0.650 |
Why?
|
| Anti-Arrhythmia Agents | 1 | 2019 | 2 | 0.650 |
Why?
|
| Mitral Valve | 5 | 2013 | 12 | 0.650 |
Why?
|
| Outpatient Clinics, Hospital | 1 | 2019 | 17 | 0.640 |
Why?
|
| Coronary Vessels | 2 | 2018 | 12 | 0.640 |
Why?
|
| Follow-Up Studies | 11 | 2017 | 370 | 0.620 |
Why?
|
| Emergencies | 1 | 2018 | 16 | 0.600 |
Why?
|
| Heart Ventricles | 1 | 2018 | 60 | 0.570 |
Why?
|
| Prognosis | 4 | 2023 | 199 | 0.570 |
Why?
|
| Predictive Value of Tests | 4 | 2023 | 188 | 0.560 |
Why?
|
| Myocardial Ischemia | 1 | 2017 | 12 | 0.560 |
Why?
|
| Intraoperative Complications | 1 | 2016 | 8 | 0.560 |
Why?
|
| Registries | 2 | 2016 | 91 | 0.550 |
Why?
|
| End Stage Liver Disease | 1 | 2016 | 5 | 0.550 |
Why?
|
| Electric Countershock | 1 | 2016 | 2 | 0.540 |
Why?
|
| Academic Medical Centers | 1 | 2016 | 30 | 0.540 |
Why?
|
| Liver Transplantation | 1 | 2016 | 55 | 0.520 |
Why?
|
| Prospective Studies | 6 | 2020 | 1160 | 0.520 |
Why?
|
| Torsades de Pointes | 1 | 2015 | 1 | 0.500 |
Why?
|
| Atrioventricular Block | 1 | 2015 | 1 | 0.500 |
Why?
|
| Cardiac Pacing, Artificial | 1 | 2015 | 2 | 0.500 |
Why?
|
| Pacemaker, Artificial | 1 | 2015 | 2 | 0.500 |
Why?
|
| Heart Conduction System | 1 | 2015 | 2 | 0.500 |
Why?
|
| Erythromycin | 1 | 2015 | 12 | 0.500 |
Why?
|
| Electrocardiography | 4 | 2016 | 35 | 0.500 |
Why?
|
| Alcoholism | 1 | 2015 | 17 | 0.500 |
Why?
|
| Antibiotic Prophylaxis | 1 | 2015 | 21 | 0.490 |
Why?
|
| Coated Materials, Biocompatible | 1 | 2014 | 2 | 0.490 |
Why?
|
| Angioplasty, Balloon, Coronary | 1 | 2014 | 3 | 0.490 |
Why?
|
| Drug-Eluting Stents | 1 | 2014 | 3 | 0.490 |
Why?
|
| Rheumatic Heart Disease | 3 | 2006 | 13 | 0.450 |
Why?
|
| Anti-Bacterial Agents | 2 | 2015 | 293 | 0.450 |
Why?
|
| Heart Injuries | 1 | 2013 | 1 | 0.450 |
Why?
|
| Echocardiography, Three-Dimensional | 1 | 2013 | 1 | 0.450 |
Why?
|
| Wounds, Stab | 1 | 2013 | 3 | 0.450 |
Why?
|
| Time Factors | 6 | 2018 | 507 | 0.440 |
Why?
|
| Heart Valve Prosthesis Implantation | 4 | 2003 | 5 | 0.440 |
Why?
|
| Renal Dialysis | 4 | 2019 | 27 | 0.430 |
Why?
|
| Streptococcus pneumoniae | 1 | 2015 | 336 | 0.400 |
Why?
|
| Pneumococcal Infections | 1 | 2015 | 299 | 0.390 |
Why?
|
| Risk Assessment | 5 | 2020 | 225 | 0.380 |
Why?
|
| Carotid Intima-Media Thickness | 6 | 2020 | 108 | 0.350 |
Why?
|
| Stroke Volume | 2 | 2023 | 43 | 0.350 |
Why?
|
| Prosthesis Design | 5 | 2014 | 11 | 0.310 |
Why?
|
| Incidence | 4 | 2019 | 685 | 0.300 |
Why?
|
| Chronic Disease | 2 | 2019 | 107 | 0.300 |
Why?
|
| Aged | 6 | 2019 | 1740 | 0.290 |
Why?
|
| Retrospective Studies | 6 | 2019 | 799 | 0.290 |
Why?
|
| Inflammation | 4 | 2021 | 104 | 0.290 |
Why?
|
| Recovery of Function | 2 | 2018 | 11 | 0.290 |
Why?
|
| Prevalence | 5 | 2019 | 1192 | 0.280 |
Why?
|
| Echocardiography | 5 | 2019 | 100 | 0.260 |
Why?
|
| Carrier Proteins | 3 | 2016 | 23 | 0.260 |
Why?
|
| Global Health | 2 | 2017 | 193 | 0.250 |
Why?
|
| Heart Valve Diseases | 3 | 1999 | 6 | 0.250 |
Why?
|
| Biomarkers | 4 | 2020 | 327 | 0.240 |
Why?
|
| Echocardiography, Transesophageal | 4 | 2013 | 4 | 0.240 |
Why?
|
| Interleukin-6 | 3 | 2020 | 51 | 0.230 |
Why?
|
| Albinism, Oculocutaneous | 2 | 2001 | 3 | 0.230 |
Why?
|
| Immunotherapy | 2 | 2014 | 7 | 0.220 |
Why?
|
| Prednisolone | 2 | 2014 | 10 | 0.220 |
Why?
|
| Prosthesis-Related Infections | 1 | 2003 | 2 | 0.220 |
Why?
|
| Pericarditis, Tuberculous | 2 | 2014 | 8 | 0.220 |
Why?
|
| Membrane Proteins | 2 | 2001 | 36 | 0.220 |
Why?
|
| Mycobacterium | 2 | 2014 | 16 | 0.220 |
Why?
|
| Kidney Failure, Chronic | 3 | 2019 | 27 | 0.220 |
Why?
|
| Case-Control Studies | 3 | 2020 | 480 | 0.220 |
Why?
|
| Gadolinium | 1 | 2023 | 5 | 0.220 |
Why?
|
| Magnetic Resonance Imaging, Cine | 1 | 2023 | 5 | 0.220 |
Why?
|
| Contrast Media | 1 | 2023 | 6 | 0.220 |
Why?
|
| Membrane Glycoproteins | 2 | 2016 | 11 | 0.220 |
Why?
|
| Animals | 4 | 2018 | 1081 | 0.220 |
Why?
|
| South Africa | 9 | 2020 | 7596 | 0.210 |
Why?
|
| Genetic Testing | 1 | 2023 | 34 | 0.210 |
Why?
|
| Polymorphism, Genetic | 2 | 2020 | 99 | 0.210 |
Why?
|
| Echocardiography, Doppler, Color | 2 | 1999 | 7 | 0.200 |
Why?
|
| Cross-Sectional Studies | 4 | 2020 | 1422 | 0.200 |
Why?
|
| Platelet Activation | 1 | 2022 | 17 | 0.190 |
Why?
|
| Blood Platelets | 1 | 2022 | 30 | 0.190 |
Why?
|
| Monophenol Monooxygenase | 1 | 2001 | 1 | 0.190 |
Why?
|
| Chromosomes, Human, Pair 15 | 1 | 2001 | 3 | 0.190 |
Why?
|
| Oxidoreductases | 1 | 2001 | 7 | 0.180 |
Why?
|
| Endocarditis, Bacterial | 1 | 2000 | 7 | 0.180 |
Why?
|
| Population Groups | 1 | 2020 | 9 | 0.180 |
Why?
|
| Apolipoprotein L1 | 1 | 2020 | 6 | 0.180 |
Why?
|
| Lipoproteins, LDL | 1 | 2020 | 9 | 0.180 |
Why?
|
| Vascular Cell Adhesion Molecule-1 | 1 | 2020 | 25 | 0.170 |
Why?
|
| Relaxin | 1 | 2019 | 1 | 0.170 |
Why?
|
| Cardiovascular Agents | 1 | 2019 | 11 | 0.170 |
Why?
|
| Vasodilator Agents | 1 | 2019 | 11 | 0.170 |
Why?
|
| Gene Expression Profiling | 1 | 2019 | 41 | 0.170 |
Why?
|
| Pulse Wave Analysis | 1 | 2020 | 61 | 0.170 |
Why?
|
| Infusions, Intravenous | 2 | 2019 | 16 | 0.170 |
Why?
|
| Fibrosis | 1 | 2019 | 11 | 0.170 |
Why?
|
| Ultrasonography | 2 | 2015 | 77 | 0.160 |
Why?
|
| Bradycardia | 1 | 2019 | 1 | 0.160 |
Why?
|
| Severity of Illness Index | 2 | 2019 | 253 | 0.160 |
Why?
|
| Coronary Angiography | 2 | 2018 | 14 | 0.160 |
Why?
|
| Antiretroviral Therapy, Highly Active | 3 | 2018 | 472 | 0.160 |
Why?
|
| Mechanotransduction, Cellular | 1 | 2018 | 1 | 0.150 |
Why?
|
| Oxidative Stress | 1 | 2018 | 19 | 0.150 |
Why?
|
| Extracellular Matrix | 1 | 2018 | 13 | 0.150 |
Why?
|
| Inflammation Mediators | 1 | 2018 | 22 | 0.150 |
Why?
|
| C-Reactive Protein | 4 | 2020 | 96 | 0.150 |
Why?
|
| Heart-Assist Devices | 1 | 2016 | 2 | 0.140 |
Why?
|
| Proteinuria | 1 | 2016 | 14 | 0.140 |
Why?
|
| Hypercholesterolemia | 1 | 2017 | 33 | 0.140 |
Why?
|
| Pericardiocentesis | 2 | 2014 | 6 | 0.140 |
Why?
|
| Water-Electrolyte Imbalance | 1 | 2016 | 4 | 0.130 |
Why?
|
| Vena Cava, Inferior | 1 | 2016 | 5 | 0.130 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2017 | 77 | 0.130 |
Why?
|
| Cardiac Volume | 1 | 2016 | 3 | 0.130 |
Why?
|
| Malnutrition | 1 | 2016 | 56 | 0.130 |
Why?
|
| Anticholesteremic Agents | 1 | 2017 | 83 | 0.130 |
Why?
|
| Cholesterol, LDL | 1 | 2017 | 150 | 0.130 |
Why?
|
| Diagnostic Errors | 1 | 2015 | 18 | 0.130 |
Why?
|
| Diagnosis, Differential | 1 | 2015 | 63 | 0.130 |
Why?
|
| Cattle | 3 | 2000 | 28 | 0.130 |
Why?
|
| Genotype | 4 | 2020 | 442 | 0.130 |
Why?
|
| Action Potentials | 1 | 2015 | 2 | 0.120 |
Why?
|
| Africa South of the Sahara | 2 | 2015 | 353 | 0.120 |
Why?
|
| Reoperation | 1 | 2014 | 8 | 0.120 |
Why?
|
| Equipment Design | 1 | 2014 | 27 | 0.120 |
Why?
|
| Aged, 80 and over | 1 | 2016 | 468 | 0.120 |
Why?
|
| Glucocorticoids | 1 | 2014 | 20 | 0.120 |
Why?
|
| Delayed Diagnosis | 1 | 2013 | 17 | 0.110 |
Why?
|
| Heart Septal Defects, Atrial | 1 | 1993 | 1 | 0.110 |
Why?
|
| Mitral Valve Stenosis | 1 | 1993 | 1 | 0.110 |
Why?
|
| Catheterization | 1 | 1993 | 6 | 0.110 |
Why?
|
| Cohort Studies | 3 | 2020 | 967 | 0.110 |
Why?
|
| Pericardial Effusion | 1 | 2012 | 6 | 0.110 |
Why?
|
| Bacterial Vaccines | 1 | 2012 | 13 | 0.100 |
Why?
|
| Treatment Failure | 3 | 2019 | 175 | 0.100 |
Why?
|
| Young Adult | 1 | 2019 | 2498 | 0.100 |
Why?
|
| Adiponectin | 1 | 2012 | 15 | 0.100 |
Why?
|
| Double-Blind Method | 3 | 2019 | 272 | 0.100 |
Why?
|
| Developing Countries | 1 | 2014 | 400 | 0.100 |
Why?
|
| Stents | 2 | 1999 | 10 | 0.080 |
Why?
|
| Peritoneal Dialysis | 2 | 2016 | 10 | 0.070 |
Why?
|
| Rheumatic Fever | 1 | 2006 | 4 | 0.070 |
Why?
|
| Primary Prevention | 1 | 2006 | 27 | 0.060 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2014 | 106 | 0.060 |
Why?
|
| Sequence Deletion | 2 | 2001 | 16 | 0.060 |
Why?
|
| Prosthesis Failure | 1 | 2003 | 2 | 0.060 |
Why?
|
| Probability | 1 | 2003 | 27 | 0.060 |
Why?
|
| Echocardiography, Doppler | 1 | 2003 | 18 | 0.060 |
Why?
|
| Postoperative Complications | 1 | 2003 | 34 | 0.060 |
Why?
|
| Gene Frequency | 2 | 2020 | 122 | 0.050 |
Why?
|
| Disabled Children | 1 | 2002 | 1 | 0.050 |
Why?
|
| Intellectual Disability | 1 | 2002 | 5 | 0.050 |
Why?
|
| Phosphoproteins | 1 | 2022 | 10 | 0.050 |
Why?
|
| Endothelial Cells | 1 | 2022 | 14 | 0.050 |
Why?
|
| Myocardium | 1 | 2022 | 35 | 0.050 |
Why?
|
| Coronary Restenosis | 1 | 2021 | 4 | 0.050 |
Why?
|
| Centromere | 1 | 2001 | 1 | 0.050 |
Why?
|
| Lod Score | 1 | 2001 | 1 | 0.050 |
Why?
|
| Coronary Artery Bypass | 1 | 2021 | 4 | 0.050 |
Why?
|
| Genetic Markers | 1 | 2001 | 11 | 0.050 |
Why?
|
| Spike Glycoprotein, Coronavirus | 1 | 2022 | 101 | 0.050 |
Why?
|
| Chromosome Mapping | 1 | 2001 | 20 | 0.050 |
Why?
|
| Telomere | 1 | 2001 | 17 | 0.050 |
Why?
|
| Pedigree | 1 | 2001 | 30 | 0.050 |
Why?
|
| Toll-Like Receptor 4 | 1 | 2020 | 6 | 0.040 |
Why?
|
| Molecular Sequence Data | 1 | 2001 | 263 | 0.040 |
Why?
|
| Kidney Function Tests | 1 | 2020 | 12 | 0.040 |
Why?
|
| Disease Susceptibility | 1 | 2020 | 46 | 0.040 |
Why?
|
| Haplotypes | 1 | 2001 | 125 | 0.040 |
Why?
|
| Risk | 1 | 2020 | 87 | 0.040 |
Why?
|
| DNA | 1 | 2020 | 73 | 0.040 |
Why?
|
| Membrane Transport Proteins | 1 | 2000 | 4 | 0.040 |
Why?
|
| Peritoneal Dialysis, Continuous Ambulatory | 1 | 2019 | 2 | 0.040 |
Why?
|
| Acute Disease | 1 | 2019 | 105 | 0.040 |
Why?
|
| Recombinant Proteins | 1 | 2019 | 73 | 0.040 |
Why?
|
| Coronary Circulation | 1 | 1999 | 10 | 0.040 |
Why?
|
| Ventricular Pressure | 1 | 1999 | 5 | 0.040 |
Why?
|
| Blood Flow Velocity | 1 | 1999 | 17 | 0.040 |
Why?
|
| Disease Progression | 1 | 2019 | 154 | 0.040 |
Why?
|
| Hypertrophy, Left Ventricular | 1 | 2019 | 65 | 0.040 |
Why?
|
| Italy | 1 | 2018 | 3 | 0.040 |
Why?
|
| Mutation | 1 | 2000 | 306 | 0.040 |
Why?
|
| Rural Population | 1 | 2002 | 654 | 0.040 |
Why?
|
| Genetic Carrier Screening | 1 | 1997 | 12 | 0.040 |
Why?
|
| Injections, Subcutaneous | 1 | 2017 | 22 | 0.040 |
Why?
|
| Prenatal Diagnosis | 1 | 1997 | 22 | 0.040 |
Why?
|
| Antibodies | 1 | 2017 | 25 | 0.030 |
Why?
|
| Blood Pressure | 1 | 2019 | 317 | 0.030 |
Why?
|
| Proprotein Convertase 9 | 1 | 2017 | 43 | 0.030 |
Why?
|
| Transplant Recipients | 1 | 2016 | 6 | 0.030 |
Why?
|
| Lipids | 1 | 2017 | 81 | 0.030 |
Why?
|
| Graft Survival | 1 | 2016 | 40 | 0.030 |
Why?
|
| Spectrum Analysis | 1 | 2016 | 8 | 0.030 |
Why?
|
| Electric Impedance | 1 | 2016 | 8 | 0.030 |
Why?
|
| Kidney Transplantation | 1 | 2016 | 42 | 0.030 |
Why?
|
| Hospitalization | 1 | 2019 | 418 | 0.030 |
Why?
|
| Hospitals, Public | 1 | 2016 | 45 | 0.030 |
Why?
|
| Heart | 1 | 2016 | 27 | 0.030 |
Why?
|
| Endotoxins | 1 | 2016 | 6 | 0.030 |
Why?
|
| Extracellular Fluid | 1 | 2016 | 5 | 0.030 |
Why?
|
| Edema | 1 | 2016 | 7 | 0.030 |
Why?
|
| Acute-Phase Proteins | 1 | 2016 | 14 | 0.030 |
Why?
|
| Nutritional Status | 1 | 2016 | 76 | 0.030 |
Why?
|
| Hemophilia A | 1 | 1997 | 106 | 0.030 |
Why?
|
| Myocardial Reperfusion | 1 | 2014 | 1 | 0.030 |
Why?
|
| Purinergic P2Y Receptor Antagonists | 1 | 2014 | 1 | 0.030 |
Why?
|
| Platelet Aggregation Inhibitors | 1 | 2014 | 12 | 0.030 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2014 | 29 | 0.030 |
Why?
|
| Pericarditis, Constrictive | 1 | 2014 | 2 | 0.030 |
Why?
|
| Cardiac Tamponade | 1 | 2014 | 3 | 0.030 |
Why?
|
| Combined Modality Therapy | 1 | 2014 | 25 | 0.030 |
Why?
|
| Body Composition | 1 | 2016 | 153 | 0.030 |
Why?
|
| Europe | 1 | 2014 | 56 | 0.030 |
Why?
|
| Recurrence | 1 | 2014 | 29 | 0.030 |
Why?
|
| Social Class | 1 | 2014 | 73 | 0.030 |
Why?
|
| Anticoagulants | 1 | 2014 | 57 | 0.030 |
Why?
|
| United States | 1 | 2014 | 132 | 0.030 |
Why?
|
| Multivariate Analysis | 1 | 2014 | 171 | 0.030 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2014 | 58 | 0.030 |
Why?
|
| Proportional Hazards Models | 1 | 2014 | 163 | 0.030 |
Why?
|
| Poverty | 1 | 2014 | 152 | 0.030 |
Why?
|
| Reverse Transcriptase Inhibitors | 1 | 2014 | 118 | 0.030 |
Why?
|
| Cardiac Output | 1 | 1993 | 4 | 0.030 |
Why?
|
| Analysis of Variance | 1 | 1993 | 64 | 0.030 |
Why?
|
| Hemodynamics | 1 | 1993 | 32 | 0.030 |
Why?
|
| Cause of Death | 1 | 2014 | 221 | 0.030 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2012 | 21 | 0.030 |
Why?
|
| Pilot Projects | 1 | 2012 | 179 | 0.020 |
Why?
|
| Cholesterol, HDL | 1 | 2012 | 32 | 0.020 |
Why?
|
| Triglycerides | 1 | 2012 | 47 | 0.020 |
Why?
|
| CD4 Lymphocyte Count | 1 | 2014 | 656 | 0.020 |
Why?
|
| Linear Models | 1 | 2012 | 83 | 0.020 |
Why?
|
| Antitubercular Agents | 1 | 2012 | 322 | 0.020 |
Why?
|
| Marfan Syndrome | 1 | 1988 | 2 | 0.020 |
Why?
|
| Pulmonary Artery | 1 | 1988 | 4 | 0.020 |
Why?
|
| Aneurysm | 1 | 1988 | 3 | 0.020 |
Why?
|
| Africa | 1 | 2006 | 376 | 0.010 |
Why?
|
| Health Status | 1 | 2002 | 111 | 0.010 |
Why?
|
| Codon, Terminator | 1 | 2000 | 3 | 0.010 |
Why?
|
| Genes, Recessive | 1 | 2000 | 5 | 0.010 |
Why?
|
| Pigmentation | 1 | 2000 | 2 | 0.010 |
Why?
|
| Polymorphism, Single-Stranded Conformational | 1 | 2000 | 11 | 0.010 |
Why?
|
| Exons | 1 | 2000 | 17 | 0.010 |
Why?
|
| DNA Mutational Analysis | 1 | 2000 | 34 | 0.010 |
Why?
|
| Amino Acid Substitution | 1 | 2000 | 35 | 0.010 |
Why?
|
| Surveys and Questionnaires | 1 | 2002 | 563 | 0.010 |
Why?
|
| Phenotype | 1 | 2000 | 158 | 0.010 |
Why?
|
| Genetic Variation | 1 | 2000 | 175 | 0.010 |
Why?
|
| Introns | 1 | 1997 | 13 | 0.010 |
Why?
|
| Chromosome Inversion | 1 | 1997 | 9 | 0.010 |
Why?
|
| Founder Effect | 1 | 1997 | 16 | 0.010 |
Why?
|
| Child, Preschool | 1 | 2002 | 1748 | 0.010 |
Why?
|
| Child | 1 | 2002 | 2242 | 0.010 |
Why?
|
| Pregnancy | 1 | 1997 | 1862 | 0.010 |
Why?
|
| Aortic Aneurysm | 1 | 1988 | 1 | 0.000 |
Why?
|
| Radiography | 1 | 1988 | 80 | 0.000 |
Why?
|